NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis $7.95 +0.52 (+7.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$8.02 +0.07 (+0.82%) As of 10/3/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Day One Biopharmaceuticals Stock (NASDAQ:DAWN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DAWN alerts:Sign Up Key Stats Today's Range$7.47▼$8.2850-Day Range$5.80▼$7.9552-Week Range$5.64▼$16.76Volume3.24 million shsAverage Volume1.19 million shsMarket Capitalization$814.32 millionP/E RatioN/ADividend YieldN/APrice Target$25.29Consensus RatingModerate Buy Company Overview Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit. The company’s pipeline includes several small-molecule candidates in various stages of development. The lead program, D1-B701, is a selective FGFR4 inhibitor designed to treat FGF19-driven hepatocellular carcinoma and other solid tumors. Additional programs include D1-H201, a selective HDAC6 inhibitor for certain hematologic malignancies, and D1-R199, a RET kinase inhibitor targeting RET fusion-positive cancers. Each program is supported by companion diagnostic strategies aimed at enriching patient populations and optimizing clinical outcomes. Founded in 2017, Day One Biopharmaceuticals is headquartered in San Diego, California, and maintains research and development operations in both the United States and Asia. The company’s leadership team comprises professionals with extensive experience in oncology drug discovery, clinical development, regulatory affairs and commercial strategy. Day One collaborates with academic and industry partners to advance its pipeline and remains committed to addressing significant unmet needs in cancer therapeutics through scientifically rigorous and patient-focused innovation.AI Generated. May Contain Errors. Read More Day One Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreDAWN MarketRank™: Day One Biopharmaceuticals scored higher than 61% of companies evaluated by MarketBeat, and ranked 417th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDay One Biopharmaceuticals has a consensus price target of $25.29, representing about 218.1% upside from its current price of $7.95.Amount of Analyst CoverageDay One Biopharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Day One Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($0.72) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -8.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -8.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Day One Biopharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.03% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 0.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.03% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 0.53%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News Sentiment0.92 News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Day One Biopharmaceuticals this week, compared to 4 articles on an average week.Search Interest9 people have searched for DAWN on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows5 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,557.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DAWN Stock News HeadlinesAnalysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $25.29September 27, 2025 | americanbankingnews.comPiper Sandler Starts Coverage on Day One (DAWN) with Overweight RatingSeptember 8, 2025 | insidermonkey.comShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.October 4 at 2:00 AM | Brownstone Research (Ad)Day One Biopharmaceuticals initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comH.C. Wainwright Reiterates ‘Buy’ Rating on Day One Biopharmaceuticals, Inc. (DAWN)August 19, 2025 | insidermonkey.comDay One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)August 7, 2025 | seekingalpha.comDay One price target lowered to $25 from $36 at H.C. WainwrightAugust 7, 2025 | msn.comDay One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...August 6, 2025 | finance.yahoo.comSee More Headlines DAWN Stock Analysis - Frequently Asked Questions How have DAWN shares performed this year? Day One Biopharmaceuticals' stock was trading at $12.67 at the beginning of the year. Since then, DAWN stock has decreased by 37.3% and is now trading at $7.95. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) issued its earnings results on Tuesday, August, 5th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06. The firm earned $33.91 million during the quarter, compared to the consensus estimate of $35.55 million. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative trailing twelve-month return on equity of 19.01%. Read the conference call transcript. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Day One Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings8/05/2025Today10/03/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year Founded2018Price Target and Rating Average Price Target for Day One Biopharmaceuticals$25.29 High Price Target$34.00 Low Price Target$16.00 Potential Upside/Downside+218.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.50 million Net Margins-50.63% Pretax Margin-47.65% Return on Equity-19.01% Return on Assets-16.99% Debt Debt-to-Equity RatioN/A Current Ratio9.65 Quick Ratio9.53 Sales & Book Value Annual Sales$131.16 million Price / Sales6.21 Cash FlowN/A Price / Cash FlowN/A Book Value$4.99 per share Price / Book1.59Miscellaneous Outstanding Shares102,430,000Free Float96,081,000Market Cap$814.32 million OptionableOptionable Beta-1.26 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DAWN) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.